Skip to main content
. 2019 Jan 3;33(1):281–287. doi: 10.21873/invivo.11473

Table II. Multivariate analysis of survival after recurrence.

graphic file with name in_vivo-33-284-i0001.jpg

ER, Estrogen receptor; A/T, anthracycline or taxane chemotherapy; ET, endocrine therapy; TFI, treatment-free interval; DFI, disease-free interval; 1L, first-line.